Selenium decreases thyroid cancer cell growth by increasing expression of GADD153 and GADD34

Nutrition and Cancer

Volumn 62, Issue 1, 2010, Pages 66-73

  Kato, Meredith A ^a   Finley, David J ^a   Lubitz, Carrie C ^a   Zhu, Baixin ^a   Moo, Tracy Ann ^a   Loeven, Michael R ^a   Ricci, Joseph A ^a   Zarnegar, Rasa ^a   Katdare, Meena ^a   Fahey, Thomas J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 34; NUCLEIC ACID BINDING PROTEIN; SELENIUM DERIVATIVE; SELENO L METHIONINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA DAMAGE; DOSE TIME EFFECT RELATION; DRUG INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NICK END LABELING; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; THYROID CANCER; UPREGULATION; WESTERN BLOTTING;

ANTIGENS, DIFFERENTIATION; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; DNA DAMAGE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; IN SITU NICK-END LABELING; MICROARRAY ANALYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SELENIUM; SELENOMETHIONINE; THYROID NEOPLASMS; TRANSCRIPTION FACTOR CHOP;

EID: 74249113825     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580903191569     Document Type: Article

References (40)

1. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH, et al.: Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 11, 630-639, 2002.
2. Redman C, Scott JA, Baines AT, Basye JL, Clark LC, et al.: Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett 125, 103-110, 1998.
3. Goel A, Fuerst F, Hotchkiss E, and Boland CR: Selenomethionine induces p53 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cancer Biol Ther 5, 529-535, 2006.
4. Swede H, DongY, Reid M, Marshall J, and IpC:Cell cycle arrest biomarkers in human lung cancer cells after treatment with selenium in culture. Cancer Epidemiol Biomarkers Prev 12(11 Pt. 1), 1248-1252, 2003.
5. Ip C, Thompson HJ, Zhu Z, and Ganther HE: In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 60, 2882-2886, 2000.
6. Sinha R, Kiley SC, Lu JX, Thompson HJ, Moraes R, et al.: Effects of methylselenocysteine on PKC activity, cdk2 phosphorylation and GADD gene expression in synchronized mouse mammary epithelial tumor cells. Cancer Lett 146, 135-145, 1999.
7. Novoselov SV, Calvisi DF, Labunskyy VM, Factor VM, Carlson BA, et al.: Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene 24, 8003-8011, 2005.
8. Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, et al.: Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 66, 1070-1075, 2006.
9. Yu SY, Zhu YJ, and Li WG: Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Res 56, 117-124, 1997.
10. Rayman MP: The importance of selenium to human health. Lancet 356, 233-241, 2000.
11. Kucharzewski M, Braziewicz J, Majewska U, and Gozdz S: Copper, zinc, and selenium in whole blood and thyroid tissue of people with various thyroid diseases. Biol Trace Elem Res 93, 9-18, 2003.
12. Glattre E, Thomassen Y, Thoresen SO, Haldorsen T, Lund-Larsen PG, et al.: Prediagnostic serum selenium in a case-control study of thyroid cancer. Int J Epidemiol 18, 45-49, 1989.
13. Moncayo R, Kroiss A, Oberwinkler M, Karakolcu F, Starzinger M, et al.: The role of selenium, vitamin C, and zinc in benign thyroid diseases and of selenium in malignant thyroid diseases: low selenium levels are found in subacute and silent thyroiditis and in papillary and follicular carcinoma. BMC Endocr Disord 8, 2, 2008.
14. Finley DJ, Arora N, Zhu B, Gallagher L, Fahey TJ III: Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89, 3214-3223, 2004.
15. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, et al.: Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 9, 1792 - 1800, 2003.
16. Kaeck M, Lu J, Strange R, Ip C, Ganther HE, et al.: Differential induction of growth arrest inducible genes by selenium compounds. Biochem Pharmacol 53, 921-926, 1997.
17. Dong Y, Ganther HE, Stewart C, and Ip C: Identification of molecular targets associated with selenium-induced growth inhibition in human breast cells using cDNA microarrays. Cancer Res 62, 708-714, 2002.
18. Dong Y, Zhang H, Hawthorn L, Ganther HE, and Ip C: Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 63, 52-59, 2003.
19. Gavrieli Y, Sherman Y, and Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119, 493-501, 1992.
20. Finley DF, Zhu B, Barden CB, and Fahey TJ III: Discrimination of Benign and Malignant Thyroid Nodules by Molecular Profiling. Ann Surg 240, 425-436, 2004.
21. Rozen S and Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132, 365-386, 2000.
22. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al.: Cancer statistics, 2008. CA Cancer J Clin 58, 71-96, 2008.
23. Venkateswaran V, Klotz LH, and Fleshner NE: Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res 62, 2540-2545, 2002.
24. Zeng H and Combs GF Jr.: Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem 19, 1-7, 2008.
25. Last K, Maharaj L, Perry J, Strauss S, Fitzgibbon J, et al.: The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumors. Ann Oncol 17, 773-779, 2006.
26. El-Bayoumy K and Sinha R: Molecular chemoprevention by selenium: a genomic approach. Mutat Res 591, 224-236, 2005.
27. Zhan Q, Lord KA, Alamo I Jr, Hollander MC, Carrier F, et al.: The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth. Mol Cell Biol 14, 2361-2371, 1994.
28. Zinszner H,Kuroda M,Wang X, Batchvarova N, Lightfoot RT, et al.: CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 12, 982-995, 1998.
29. Oh-Hashi K, Maruyama W, and Isobe K: Peroxynitrite induces GADD34, 45, and 153 VIA p38 MAPK in human neuroblastoma SH-SY5Y cells. Free Radic Biol Med 30, 213-221, 2001.
30. Ridd K, Alexander DJ, and Reed CJ: Foetal rat lung epithelial (FRLE) cells: alterations in cellular homeostasis and gene expression in response to etoposide, hydrogen peroxide and sodium butyrate. Toxicology 195, 209-220, 2004.
31. Ou YC, Thompson SA, Kirchner SC, Kavanagh TJ, and Faustman EM: Induction of growth arrest and DNA damage-inducible genes Gadd45 and Gadd153 in primary rodent embryonic cells following exposure to methylmercury. Toxicol Appl Pharmacol 147, 31-38, 1997.
32. Szymczyk KH, Shapiro IM, and Adams CS: Ionizing radiation sensitizes bone cells to apoptosis. Bone 34, 148-156, 2004.
33. Pan MH, Chang YH, Badmaev V, Nagabhushanam K, and Ho CT: Pterostilbene induces apoptosis and cell cycle arrest in human gastric carcinoma cells. J Agric Food Chem 55, 7777-7785, 2007.
34. Pan MH, Hsieh MC, Kuo JM, Lai CS, Wu H, et al.: 6-Shogaol induces apoptosis in human colorectal carcinoma cells via ROS production, caspase activation, and GADD 153 expression. Mol Nutr Food Res 52, 527-537, 2008.
35. Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358, 1160-1174, 2008.
36. Kanazawa M, Satomi Y, Mizutani Y, Ukimura O, Kawauchi A, et al.: Isoliquiritigenin inhibits the growth of prostate cancer. Eur Urol 43, 580-586, 2003.
37. Marilley D and Schwaller B: Association between the calcium-binding protein calretinin and cytoskeletal components in the human colon adenocarcinoma cell line WiDr. Exp Cell Res 259, 12-22, 2000.
38. Gander JC, Gotzos V, Fellay B, and Schwaller B: Inhibition of the proliferative cycle and apoptotic events in WiDr cells after down-regulation of the calcium-binding protein calretinin using antisense oligodeoxynucleotides. Exp Cell Res 225, 399-410, 1996.
39. Younes MN, Yazici YD, Kim S, Jasser SA, El-Naggar AK, et al.: Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin Cancer Res 12(11 Pt. 1), 3425-3434, 2006.
40. Lee YM, Ting CM, Cheng YK, Fan TP, Wong RN, et al.: Mechanisms of 2-methoxyestradiol-induced apoptosis and G2/M cell-cycle arrest of nasopharyngeal carcinoma cells. Cancer Lett 268, 295-307, 2008.